Symbicort® (budesonide/formoterol) Asthma

This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Asthma ICS/LABAs and Symbicort®

The window of opportunity

SMART dosing delivers the inhaled corticosteroids (ICS) to treat the underlying inflammation as needed.5

SMART as a single inhaler allows for an increase in ICS, as symptoms worsen, to help reduce the severity of an asthma attack.5

Hypothetical outcome refers to the hypothesised reduction in night time symptoms and requirement for SABA rescue use when budesonide and formoterol are used together during the "window of opportunity"6

The FACET study was a double-blind, randomised, parallel-group study comparing the effect of low- and high-dose budesonide with and without twice daily treatment with formoterol. Following a 1600µg budesonide per day 4-week run-in period, 852 patients were randomised to receive either: budesonide 100µg + placebo, budesonide 100µg + formoterol, budesonide 400µg + placebo or budesonide 400µg + formoterol twice daily for 12 months. Patients were 18 to 70 years old, had asthma for at least 6 months, taken an inhaled corticosteroid for at least 3 months and a baseline FEV1 50% of predicted or more.6

*Severe exacerbations defined by a fall in morning peak expiratory flow (PEF) of more than 30% from baseline values during the run-in period on two consecutive days, or as the need for a course of oral corticosteroids as judged by the clinical investigator.6

Comparison of change in evening PEF, night time symptoms and SABA rescue use during an exacerbation. Data were standardised (Day –14 = 0%,Day –0 = 100%) to allow comparison of changes with time between different end points.